Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals (IRWD) is a leader in gastrointestinal therapeutics, pioneering treatments for chronic conditions like IBS-C and CIC. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative updates including earnings reports, research breakthroughs, and partnership announcements. Our curated collection ensures you never miss critical information about IRWD's FDA submissions, pipeline advancements, or market expansion strategies.
Discover comprehensive coverage of:
• Clinical trial results
• Drug development progress
• Strategic collaborations
• Regulatory updates
Bookmark this page for streamlined access to verified information directly impacting IRWD's position in the biopharmaceutical sector.
Ironwood Pharmaceuticals presented pivotal Phase III trial data at Digestive Disease Week® 2024, highlighting the efficacy and safety of the once-weekly subcutaneous apraglutide in adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial, called STARS, showed significant reductions in weekly parenteral support (PS) volume, with apraglutide patients achieving more days off PS and higher clinical responder rates compared to placebo. Notably, some patients achieved enteral autonomy. The study demonstrated apraglutide's well-tolerated safety profile, consistent with previous trials. Ironwood plans to submit a new drug application to the FDA based on these results, potentially offering a new treatment option for SBS-IF patients.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported positive Phase III results for apraglutide in adult patients with SBS-IF and explored SR GI aGVHD. LINZESS EUTRx demand grew by 10% YoY. FY 2024 guidance revised due to LINZESS gross-to-net change. Financial highlights include total revenue of $74.9 million, GAAP net loss of $4.2 million, and adjusted EBITDA of $12.8 million.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management will engage in a fireside chat at 10:00 a.m. ET at the New York Hilton Midtown. The event will be live streamed on the company's website. A replay will be available for 1 year.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will present new data on once-weekly apraglutide in short bowel syndrome with intestinal failure (SBS-IF) at the 2024 Digestive Disease Week®. The pivotal Phase III STARS study's findings and the STARS Nutrition Study will be highlighted, alongside additional posters focusing on linaclotide, irritable bowel syndrome, and functional constipation. Apraglutide data from the STARS trial aims to reduce parenteral support (PS) dependency in adult SBS-IF patients, with plans for a new drug application submission to the FDA.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
